The COBRA Study has 2 groups. If you participate, you would be assigned to only one of these two groups, based on randomization – a process through which you have equal chance of being in one or the other group, but based completely on chance.
If you are in the first group, your treatment will be the same as it would be if you were not in the study, surgery only with close follow-up. You will receive regular check-ups with your doctor after you join the study, but no further treatments will be given to you for your colon cancer.You will have blood collected at different time points when you would be in the doctor’s office anyway, and your blood samples will be stored and tested in the future for ctDNA.
If you are in the second group, your blood will be tested at the beginning of the study, and your treatment will be determined by whether or not ctDNA is found in your blood. If ctDNA is found in your blood, you will receive chemotherapy for about 6 months after joining the study. The treatment will be one of the usual chemotherapy regimens for colon cancer: 5-fluorouracil (5-FU), leucovorin, and oxaliplatin (mFOLFOX6); or capecitabine and oxaliplatin (CAPOX). Your doctor will decide which of these regimens you receive. If ctDNA is not detected in your blood, you will receive regular check-ups with your doctor after you join the study, but will not receive any further treatment after surgery for your colon cancer, similar to if you were not in the study.